Telix Pharmaceuticals (NASDAQ:TLX) Earns Outperform Rating from Wedbush

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating reissued by equities researchers at Wedbush in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $22.00 price objective on the stock. Wedbush‘s price objective would indicate a potential upside of 118.80% from the company’s current price.

Other equities analysts have also issued research reports about the stock. Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, September 21st. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a report on Friday, September 25th. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. Finally, Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Telix Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $20.50.

Telix Pharmaceuticals Stock Performance

Shares of NASDAQ:TLX traded down $1.11 during midday trading on Wednesday, hitting $10.06. 379,689 shares of the company’s stock traded hands, compared to its average volume of 233,914. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.85 and a current ratio of 2.01. The firm’s fifty day moving average price is $11.49 and its two-hundred day moving average price is $10.78. Telix Pharmaceuticals has a twelve month low of $6.28 and a twelve month high of $13.11.

Institutional Investors Weigh In On Telix Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hennion & Walsh Asset Management Inc. purchased a new stake in Telix Pharmaceuticals during the 2nd quarter worth $1,731,000. Private Advisor Group LLC increased its stake in Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after buying an additional 128,070 shares during the period. XY Capital Ltd increased its stake in Telix Pharmaceuticals by 468.0% during the 2nd quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after buying an additional 58,739 shares during the period. WoodTrust Financial Corp purchased a new stake in Telix Pharmaceuticals during the 3rd quarter worth $186,000. Finally, Bank of America Corp DE increased its stake in Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after buying an additional 8,423 shares during the period.

Key Telix Pharmaceuticals News

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Quarterly revenue growth and reaffirmed outlook: Telix reported 19% year-over-year revenue growth for the third quarter of 2026 and reaffirmed its full-year 2026 guidance. Maintaining the forecast reduces concerns about a potential outlook cut. Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance And Advances Pipeline Programs
• Positive Sentiment: Pipeline and manufacturing initiatives advanced: Telix highlighted continued progress in its pipeline programs and collaborations intended to expand U.S. production of isotopes used in cancer therapies. These efforts could support longer-term product availability and growth. Telix Reports Third Quarter 2026 Financial Performance
• Positive Sentiment: Analyst remains bullish: Wedbush reaffirmed its “outperform” rating and set a $22 price target, signaling substantial potential upside from recent trading levels and continued confidence in Telix’s growth prospects.
• Neutral Sentiment: Strategic isotope partnerships: Telix is working with Ekalia, IBA and Framatome to help advance U.S. production of astatine-211, an isotope being explored for targeted cancer therapies. The initiative strengthens Telix’s strategic positioning, although commercial benefits are likely longer term. Telix Joins With IBA And Framatome To Help Advance Astatine-211 Production
• Negative Sentiment: Investors sold the news: Despite the reported growth and maintained guidance, coverage describes Telix shares as falling sharply. The reaction suggests investors may have been expecting stronger results or additional positive guidance, making near-term sentiment negative. Telix shares crashing 8% today: What happened?

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its programs are designed to support precision medicine by using radioactive compounds to image specific biological targets or deliver radiation directly to diseased tissue.

The company’s principal commercial product is Illuccix, a kit used to prepare gallium Ga 68 gozetotide injection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.